Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 7,601–7,700 of 15,747
Acantholytic Dyskeratosis Post-COVID Vaccination
Yang, K., Prussick, L., Hartman, R., & Mahalingam, M. (2022) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000002150 · Cited by 10
Kishimoto, M., Ishikawa, T., & Odawara, M. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0629 · Cited by 9
“Large phase-3 tri‐ als for mRNA vaccines, BNT162b2 and mRNA-1273, demonstrated that both vaccines were >94% effective against symptomatic COVID-19 [71, 74].”
BackgroundAn outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19
Monzavi, S. M., Naderi, M., Ahmadbeigi, N., Kajbafzadeh, A. M., & Muhammadnejad, S. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104398 · Cited by 9
Hajsadeghi, S., Mesgarha, M. G., Shahrbabaki, E. S., et al. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.07.021 · Cited by 9
“[3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated Healthcare Workers
Błaszczuk, A., Michalski, A., Malm, M., Drop, B., & Polz‐Dacewicz, M. (2022) · Vaccines · doi:10.3390/vaccines10081169 · Cited by 11
“Previous studies have shown the high efficacy and safety of the vaccine [6,7].”
BackgroundÖztop, N., Demir, S., Toprak, İ. D., Ünal, D., & Gelincik, A. A. (2022) · Allergy and Asthma Proceedings · doi:10.2500/aap.2022.43.220069 · Cited by 10
Galgut, O., Ashford, F. B., Deeks, A. S., Ghataure, A., Islam, M., Sambhi, T., Ker, Y. W., Duncan, C. J. A., de Silva, T. I., Hopkins, S., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100546 · Cited by 11
Quiroga, B., Soler, M. J., Ortíz, A., & de Sequera, P. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.04.005 · Cited by 10
Follmann, D. A., Janes, H., Chu, E., Jayashankar, L., Petropoulos, C. J., Serebryannyy, L., Carroll, R., Jean‐Baptiste, N., Narpala, S., Lin, B. C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad069 · Cited by 14
Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study
Neuberger, A., Eyal, N., Biber, A., Avni, C., Adi, B., Drorit, A., Petersiel, N., Hajar, D., Rakedzon, S., & Schwartz, E. (2021) · Journal of Travel Medicine · doi:10.1093/jtm/taab071 · Cited by 9
Plotkin, S. A., & Halsey, N. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab068 · Cited by 10
Hao, M., Edmonds, C. E., Nachiappan, A. C., et al. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.27118 · Cited by 9
Cancer patients and internal medicine patients attitude towards COVID-19 vaccination in Poland
Kufel-Grabowska, J., Bartoszkiewicz, M., Ramlau, R., & Litwiniuk, M. M. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/138962 · Cited by 11
CRISPR—a challenge for national and international regulation
Nicol, D. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0014 · Cited by 10
Lin, Y., Ma, B., Yang, Y., Chen, Y., Huang, J., Li, W., Yu, X., & Liang, L. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.2047 · Cited by 9
Colavita, F., Meschi, S., Gruber, C. E. M., Rueca, M., Vairo, F., Matusali, G., Lapa, D., Giombini, E., Carli, G. D., Spaziante, M., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.815870 · Cited by 9
Ogrič, M., Žigon, P., Sodin‐Šemrl, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010211 · Cited by 9
“Initial trials confirmed the safety of the mRNA vaccine [23], but due to the short development timelines, active investigation of potential adverse effects, including autoimmune reactions, is of utmost importance.”
BackgroundWhy do people consent to receiving SARS-CoV-2 vaccinations? A representative survey in Germany
Walach, H., Ofner, M., Ruof, V., Herbig, M., & Klement, R. J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060555 · Cited by 14
“Age Years: Median (range) Years: Mean±SD 52 (16-88) 49.”
Magalis, B. R., Mavian, C. N., Tagliamonte, M. S., Rich, S. N., Cash, M. N., Riva, A., Loeb, J. C., Norris, M. H., Amador, D. M., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27726 · Cited by 10
“the time) against severe disease caused by currently known variants.(15) While these individuals presented with only mild symptoms (or no symptoms at all), the number of vaccine breakthrough cases might be expected to be under‐reported.”
BackgroundMethodPathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice
Enomoto, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315027 · Cited by 11
Study of humoral and cellular immunity in vaccinated with mRNA‐1273
Gutiérrez‐Bautista, J. F., López‐Nevot, M. Á., Gómez-Vicente, E., Quesada, T., Marín, E. M., Rodríguez, A. I. E., Rodríguez, A. I. E., Rodríguez‐Granger, J., Cobo, F., & Sampedro, A. (2022) · Apmis · doi:10.1111/apm.13215 · Cited by 11
“In addition, higher levels of antibodies have been detected in vaccinated with Moderna than by Pfizer [16].”
InfluentialPinnawala, N., Thrastardottir, T. O., & Constantinou, C. (2021) · Current Nutrition Reports · doi:10.1007/s13668-021-00356-2 · Cited by 10
Jahn, M., Korth, J., Dorsch, O., Anastasiou, O. E., Krawczyk, A., Brochhagen, L., van de Sand, L., Sorge-Hädicke, B., Tyczynski, B., Witzke, O., et al. (2022) · Vaccines · doi:10.3390/vaccines10020327 · Cited by 9
Cytologic and histologic features of COVID-19 post-vaccination lymphadenopathy
Garcı́a-Molina, F., Cegarra-Navarro, M. F., Andrade-Gonzales, R. J., et al. (2021) · CytoJournal · doi:10.25259/cytojournal_21_2021 · Cited by 9
“[1] In Moderna’s case, 1.1% of the study’s patients were reported [2] whose ultrasound and pathological morphology must be known in order not to incur in diagnostic errors, especially taking into account that these postvaccinal lymphadenopathies are detected by the PET/CT. Postvaccinal…”
InfluentialSchäfer, A., Kovacs, M. S., Eder, A., et al. (2023) · Rheumatology Advances in Practice · doi:10.1093/rap/rkad065 · Cited by 9
Portillo-Blanco, A., Díez, J. R., Barrutia, O., & Guisasola, J. (2022) · Revista eureka sobre enseñanza y divulgación de las ciencias · doi:10.25267/rev_eureka_ensen_divulg_cienc.2022.v19.i1.1302 · Cited by 15
The Interface of Cancer, Their Microenvironment and Nanotechnology
Roque, N. R., Matias, D., Bal鏰-Silva, J., Ferrer, V. P., Pessoa, L. S., & Spohr, T. C. L. D. S. E. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.024035 · Cited by 11
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M. W., Cooper, D., Muik, A., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00462-4 · Cited by 9
Self-citation(2022) · doi:10.1101/2022.08.02.502529 · Cited by 9
“Furthermore, mRNA-LNP SARS-CoV-2 vaccines perform 443 remarkably well in elderly people [65, 66], while inactivated influenza virus vaccines often have 444 subpar performance with increasing age [67].”
BackgroundFabiani, M., Mateo‐Urdiales, A., Sacco, C., Fotakis, E. A., Battilomo, S., Petrone, D., Manso, M. D., Bella, A., Riccardo, F., Stefanelli, P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.074 · Cited by 10
de Joode, K., Tol, J., Hamberg, P., Balen, M. C., Kastelijn, E. A., Borgers, J. S. W., Nuij, V. J. A. A., Klaver, Y., Herder, G. J. M., Mutsaers, P., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.009 · Cited by 9
“However, as patients with cancer were often not included in vaccination trials [16,17], additional research is needed to ensure the efficacy of COVID-19 vaccination in patients with cancer [18e20].”
Nevola, R., Criscuolo, L., Beccia, D., Femine, A. D., Ruocco, R., Imbriani, S., Alfano, M., Villani, A., Russo, A., Perillo, P., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i5.800 · Cited by 9
Dunbar, E. E., Godbout, E. J., Pryor, R. J., Rozycki, H. J., & Bearman, G. M. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.62 · Cited by 9
COVID ‐19 vaccination status and disease burden in patients with sickle cell disease
Han, J., Zhang, X., Molokie, R. E., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18443 · Cited by 9
Determinants of people’s motivations to approach COVID-19 vaccination centers
Keser, C., & Rau, H. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-30244-4 · Cited by 10
Fung, K.-M., Lai, S.-J., Lin, T.-L., & Tseng, T. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.797132 · Cited by 9
Hibino, M., Watanabe, S., Kamada, R., Tobe, S., Maeda, K., Horiuchi, S., & Kondo, T. (2021) · Internal Medicine · doi:10.2169/internalmedicine.8704-21 · Cited by 9
“The vaccine against SARS-CoV-2 produces antibodies that target the spike protein on the surface of the virus, thereby preventing infection and severe disease (3-5).”
BackgroundCOVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
Oh, H.-K., Kim, E. K., Hwang, I., Kim, T. E., Lee, Y.-K., Lee, Y.-K., & Lee, Y.-K. (2021) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2021.0157 · Cited by 9
COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019–2022
Khan, A., Zhu, Y., Babcock, H. M., Busse, L. W., Duggal, A., Exline, M. C., Gaglani, M., Gibbs, K. W., Gong, M. N., Ginde, A. A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126806 · Cited by 9
Dowling, D. J., & Levy, O. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac342 · Cited by 9
Silva‐Moraes, V., Souquette, A. H., Sautto, G. A., Paciello, I., Antonelli, G., Andreano, E., Rappuoli, R., Teixeira‐Carvalho, A., & Ross, T. M. (2023) · ImmunoHorizons · doi:10.4049/immunohorizons.2300041 · Cited by 10
ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIVPreprint
Madhi, S. A., Koen, A. L., Fairlie, L., Cutland, C., Baillie, V. L., Padayachee, S. D., Dheda, K. U. J., Barnabas, S. L., Bhorat, Q. E., Briner, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-322470/v1 · Cited by 10
Mitigating COVID-19 Vaccine Waste Through a Multidisciplinary Inpatient Vaccination Initiative
Baumann, N., Chen, S., McDonald, J. R., et al. (2022) · Journal for Healthcare Quality · doi:10.1097/jhq.0000000000000337 · Cited by 9
A Comprehensive Dataset of Lipid Nanoparticle Compositions and Properties for Nucleic Acid Delivery
Song, S., Baek, J., & Seo, S. (2025) · Scientific Data · doi:10.1038/s41597-025-06456-w · Cited by 14
“The clinical success of LNPs in COVID-19 mRNA vaccines (BNT162b2, mRNA-1273) 3–6 and the approval of Onpattro (patisiran) for hereditary transthyretin amyloidosis 7,8 have validated LNPs as a leading platform for nucleic acid delivery.”
Structure-centered design of lipid-based nanocarriers to overcome biological barriers
Woo, Y., Yoon, J., Seo, Y., Han, Y., Yoo, H. Y., Sohn, H., Lee, M. H., & Lee, T. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102425 · Cited by 24
“This same formulation was assessed in a phase 2/3 randomized, placebo-controlled trial involving 43,448 participants aged 16 years or older [130].”
mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19
Kackos, C. M., Surman, S. L., Jones, B. G., Sealy, R. E., Jeevan, T., Davitt, C. J. H., Pustylnikov, S., Darling, T. L., Boon, A. C. M., Hurwitz, J. L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04240-22 · Cited by 9
“symptomatic COVID-19 caused by the ancestral strain of the virus (6, 7).”
BackgroundWalczak, P., & Janowski, M. (2021) · Global Challenges · doi:10.1002/gch2.202100004 · Cited by 10
Antibody response to SARS-CoV-2 mRNA vaccines in pregnant women and their neonatesPreprint
Prabhu, M., Murphy, E. A., Sukhu, A. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.05.438524 · Cited by 9
Liu, Q., Huang, Y., Li, Z., Li, L., Zhao, Y., & Li, M. (2022) · Angewandte Chemie · doi:10.1002/ange.202214230 · Cited by 10
Coronavirus disease 2019 vaccination-related pericarditis: a single tertiary-center experience
Collini, V., Imazio, M., Biasio, M. D., & Sinagra, G. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001365 · Cited by 9
Jennewein, M. F., Schultz, M. D., Beaver, S., Battisti, P., Bakken, J., Hanson, D., Akther, J., Zhou, F., Mohamath, R., Singh, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.10.515993 · Cited by 9
Tan, R., Huang, G., Wei, C., He, Z., Zhao, T., Shi, Y., Liu, Z., & Chen, Y. (2024) · Journal of Polymer Science · doi:10.1002/pol.20240154 · Cited by 10
Proceeding artificial intelligence technology towards vaccine designs
Zhao, F., & Zai, X. (2025) · The Innovation Life · doi:10.59717/j.xinn-life.2025.100162 · Cited by 9
Optimizing the Delivery of mRNA to Mesenchymal Stem Cells for Tissue Engineering Applications
McCormick, K., Herrero, J. M., Haas, H., Fattah, S., Heise, A., O’Brien, F. J., & Cryan, S. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00898 · Cited by 12
Roeder, A. J., Koehler, M. A., Jasbi, P., McKechnie, D., Vanderhoof, J., Edwards, B. A., González‐Moa, M. J., Seit‐Nebi, A. S., Svarovsky, S. A., & Lake, D. F. (2022) · Vaccines · doi:10.3390/vaccines10091459 · Cited by 10
“COVID-19 mRNA vaccines BNT162b2 (Pfizer) and mRNA-1273 (Moderna) dramatically reduced the incidence of severe disease and hospitalization due to SARS-CoV-2 infection [1,2].”
BackgroundCOVID-19 Vaccination in Kidney Transplant Candidates and Recipients
Ponticelli, C., & Campise, M. (2022) · Vaccines · doi:10.3390/vaccines10111808 · Cited by 11
Zoster sine herpete following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient
Tanizaki, R., & Miyamatsu, Y. (2022) · IDCases · doi:10.1016/j.idcr.2022.e01563 · Cited by 9
“During the COVID-19 pandemic, mRNA vaccination has been conducted worldwide, which has demonstrated a high efficacy rate with an acceptable safety profile [1].”
Rasouli, M., Vakilian, F., & Ranjbari, J. (2020) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x16666201221151853 · Cited by 9
O’Shea, K. M., Schuler, C. F., IV, Chen, J., Troost, J. P., Wong, P. T., Chen, K., O’Shea, D. R., Peng, W., Gherasim, C., Manthei, D. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055429 · Cited by 9
“Since all vaccines against SARS-CoV-2 immunize with spike protein (4, 5), spike antibody levels after vaccination are elevated and may not reflect neutralizing antibody activity (35).”
BackgroundLin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Seoane, R. C., Kottoor, S. H., Pieper, F. P., Lin, K., Butler, D. K., et al. (2021) · medRxiv · doi:10.1101/2021.11.10.21266168 · Cited by 9
Tam, J. C. H., Sibayan, A. C., Seow, J., Graham, C., Kurshan, A., Merrick, B., Stanton, R. J., & Doores, K. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116000 · Cited by 14
Jensen, C. B., Bech, B. H., Hansen, S. N., Rask, C. U., Fink, P., Nielsen, H. I., Dantoft, T. M., Thysen, S. M., & Rytter, D. (2023) · Human Reproduction · doi:10.1093/humrep/dead144 · Cited by 11
Mechanoresponsive Drug Delivery Systems for Vascular Diseases
Navarro, J. F., & Lomora, M. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202200466 · Cited by 11
B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients
Stefanski, A., Rincón-Arévalo, H., Schrezenmeier, E. V., Karberg, K., Szelinski, F., Ritter, J., Chen, Y., Jahrsdörfer, B., Ludwig, C., Schrezenmeier, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822885 · Cited by 12
Du, Q., Shi, T., Wang, H., Zhu, C., Yang, N., Tong, D., & Huang, Y. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1077026 · Cited by 8
“The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2020 promotes the development of nucleic acid vaccines and further proves their effectiveness of them (Lederer et al., 2020; Polack et al., 2020; Widge et al., 2020).”
BackgroundReguzova, A., Müller, M., Pagallies, F., Burri, D. J., Salomon, F., Rziha, H.-J., Bittner-Schrader, Z., Verstrepen, B. E., Böszörményi, K. P., Verschoor, E. J., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00981-2 · Cited by 11
Schoergenhofer, C., Gelbenegger, G., Hasanacevic, D., Schöner, L., Steiner, M. M., Firbas, C., Buchtele, N., Derhaschnig, U., Tanzmann, A., Model, N., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102404 · Cited by 9
Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives
Karakaş, N., Üçüncüoğlu, S., Uludağ, D., Karaoglan, B. S., Shah, K., & Öztürk, G. (2022) · Cells · doi:10.3390/cells11030465 · Cited by 11
Romero-Ibarguengoitia, M. E., González‐Cantú, A., Rivera-Salinas, D., Hernández-Ruíz, Y. G., Armendariz-Vázquez, A. G., Barco-Flores, I. A., González-Facio, R., & Sanz‐Sánchez, M. Á. (2022) · Vaccines · doi:10.3390/vaccines10071139 · Cited by 9
“PfizerBioNTech (Pfizer Inc, New York, NY, USA, and BioNTech SE, Mainz, Germany) was one of the first laboratories to develop a mRNA vaccine against SARS-CoV-2, called BNT162b2.(4,5)”
BackgroundInfluentialZhao, J., Zhu, J., Huang, C., Zhu, X., Zhu, Z., Wu, Q., & Yuan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035151 · Cited by 9
Durand, H., Bacon, S. L., Byrne, M., Farrell, K., Kenny, E., Lavoie, K. L., McGuire, B. E., McSharry, J., Meade, O., Mooney, R., et al. (2021) · HRB Open Research · doi:10.12688/hrbopenres.13237.1 · Cited by 9
Influenza vaccine and subsequent development of zoster
Wei, K., Chang, Y., & Huang, Y. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13055 · Cited by 9
Luo, C., Jiang, W., Chen, H., & Tung, T. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2146964 · Cited by 11
Yang, Y., Xiong, Y., & Xu, G. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad043 · Cited by 9
Farouq, M. A. H., Acevedo, R., Ferro, V. A., Mulheran, P. A., & Qaraghuli, M. M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116078 · Cited by 9
Seki, M. (2021) · World Journal of Virology · doi:10.5501/wjv.v10.i2.62 · Cited by 9
Kimura, M., Niwa, J., & Doyu, M. (2022) · Vaccines · doi:10.3390/vaccines10060935 · Cited by 9
“Common adverse events of these vaccines include mild to moderate reactions at the injection site, fever, fatigue, body aches, and headache [9].”
BackgroundFongaro, B., Campara, B., Moscatiello, G. Y., Luigi, A. D., Panzeri, D., Sironi, L., Bigini, P., Carretta, G., Miolo, G., Pasut, G., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123319 · Cited by 13
Stupica, D., Collinet‐Adler, S., Kejžar, N., Jagodic, Z., Poljak, M., & Klevišar, M. N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051191 · Cited by 12
“Vaccination against SARS-CoV-2 has previously been shown to prevent hospitalization in several studies [11,14,16,24].”
Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months
Eyran, T., Vaisman‐Mentesh, A., Taussig, D., Dror, Y., Aizik, L., Kigel, A., Rosenstein, S., Bahar, Y., Ini, D., Tur‐Kaspa, R., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010569 · Cited by 8
Advocacy for Migraine Relief: Strategic Planning to Eliminate the Burden
Monteith, T. (2022) · Current Pain and Headache Reports · doi:10.1007/s11916-022-01059-1 · Cited by 8
“In fact, headache is a common side effect of the COVID-19 vaccines, occurring significantly higher than placebo in the active groups that received the novel mRNA COVID-19 vaccines [14, 15] and the single-dose adenovirus vaccine [16].”
BackgroundPalacio-Castañeda, V., Egberink, R. O., Sait, A., Andrée, L., Sala, B. M., Besheli, N. H., Oosterwijk, E., Nilvebrant, J., Leeuwenburgh, S. C. G., Brock, R. E., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111944 · Cited by 8
Yanto, T. A., Lugito, N. P. H., Hwei, L. R. Y., Virliani, C., & Octavius, G. S. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7110361 · Cited by 12
Cohen, S. R., Gao, D. X., Kahn, J. S., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.09.044 · Cited by 8
“In the Pfizer/ BioNTech BNT162b2 messenger RNA (Pfizer/ BioNTech) and Moderna messenger RNA-1273 SARS-CoV-2 (Moderna) COVID-19 vaccines phase 3 clinical trials, local and systemic reactions were reported.(2,3) We sought to compare constitutional and dermatologic postimmunization side effects of the COVID19 vaccines ve…”
Female fertility under the impact of COVID-19 pandemic: a narrative review
Wang, M., Zhang, B., & Jin, L. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.19 · Cited by 11
Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa
Pakhchanian, H. H., Raiker, R., DeYoung, C., & Yang, S. X. (2022) · Clinical and Experimental Dermatology · doi:10.1111/ced.15090 · Cited by 8
Goggins, E. S., Sharma, B., Ma, J. Z., Gautam, J., & Bowman, B. T. (2022) · Health Science Reports · doi:10.1002/hsr2.854 · Cited by 8
“Initial trials of the Pfizer‐BioNTech COVID‐19 vaccine (BNT162b2) demonstrated robust antibody responses in the general population; however, patients with ESKD were excluded from these studies.(2) Data regarding SARS‐CoV‐2 vaccine humoral response in dialysis patients has recently been reviewed.”
BackgroundScaria, P. V., Rowe, C. G., Chen, B. B., Dickey, T. H., Renn, J. P., Lambert, L., Barnafo, E. K., Rausch, K. M., Tolia, N. H., & Duffy, P. E. (2022) · iScience · doi:10.1016/j.isci.2022.104739 · Cited by 10
COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective
Kusunoki, H. (2023) · Pharmacoepidemiology · doi:10.3390/pharma2030017 · Cited by 7
“A prominent specialist introduced an article showing the high efficacy of mRNA vaccines [17] in an Internet article and appeared in an Internet video himself strongly promoting vaccination [18–21].”
BackgroundLioznov, D. A., Amosova, I. V., Sheetikov, S. A., Zornikova, K. V., Serdyuk, Y. V., Efimov, G. A., Tsyferov, M. A., Khmelevskii, M. S., Afanasiev, A., Khomyakova, N. F., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278878 · Cited by 8
de Joode, K., Taal, W., Snijders, T. J., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab258 · Cited by 8
Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity
Pacheco-García, U., & Serafín‐López, J. (2023) · Vaccines · doi:10.3390/vaccines11030655 · Cited by 9
Lasagna, A., Cassaniti, I., Arena, F., Bergami, F., Percivalle, E., Comolli, G., Sarasini, A., Ferrari, A., Cicognini, D., Schiavo, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076731 · Cited by 6
“In response to the viral pandemic, several vaccines have been proposed, including novel mRNA vaccines, which have a high efficacy of over 90% [3,4].”
BackgroundCheung, K. S., Yan, V. K. C., Lam, L. K., Ye, X., Hung, I. F., Chan, E. W., & Leung, W. K. (2023) · Vaccines · doi:10.3390/vaccines11081341 · Cited by 8
“Given the high efficacy of two doses of BNT162b2 and CoronaVac (protection from symptomatic COVID-19 is 95% [30] and 70% [31], respectively), it is hardly surprising that the effects of antibiotics on increasing infection risk was only slightly elevated (5–7%) in two- or three-dose vaccine recipients in the current st…”
BackgroundEvaluation of Patients with Vaccine Allergies Prior to mRNA-Based COVID-19 Vaccination
Lim, X. R., Tan, J. W. L., Chan, G. Y. L., Hou, J., Xie, L., Goh, V. H. L., Boon, J., Lee, S. S. M., Teo, C. M., Tan, S. C., et al. (2022) · Vaccines · doi:10.3390/vaccines10071025 · Cited by 8
“Phase 1 to 3 clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines have reported a low incidence of serious adverse events and equal incidence of adverse reactions in both vaccine and placebo groups [3,4].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.